Literature DB >> 3736592

Mechanism of action of amphotericin B on Leishmania donovani promastigotes.

A K Saha, T Mukherjee, A Bhaduri.   

Abstract

The growth of Leishmania donovani promastigotes in a liquid medium was completely inhibited by amphotericin B at a concentration of 0.3 microgram ml-1 (0.3 microM). Continuous release of small molecules that absorb at 260 nm and 280 nm was observed after contact with the drug. Uptake of [U-14C]glucose was inhibited in cells treated with the drug. An immediate release of isotopic glucose and its metabolites from preloaded cells could be demonstrated after incubation with amphotericin B (0.4 microM). Inhibition of respiration by the drug was a comparatively slower process. All the above effects could be effectively prevented in the presence of either cholesterol or ergosterol. The primary site of action of amphotericin B on L. donovani promastigote cells appears to be membrane sterols that result in a loss of the permeability barrier to small metabolites. An interesting biochemical similarity, thus, emerges between flagellated protozoa and fungi.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3736592     DOI: 10.1016/0166-6851(86)90001-0

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  22 in total

1.  Treatment with triterpenic fraction purified from Baccharis uncinella leaves inhibits Leishmania (Leishmania) amazonensis spreading and improves Th1 immune response in infected mice.

Authors:  Eduardo Seiji Yamamoto; Bruno Luiz S Campos; Márcia Dalastra Laurenti; João H G Lago; Simone dos Santos Grecco; Carlos E P Corbett; Luiz Felipe D Passero
Journal:  Parasitol Res       Date:  2013-10-31       Impact factor: 2.289

2.  Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.

Authors:  V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

3.  The plasma-membrane Ca2+-ATPase of Leishmania donovani is an extrusion pump for Ca2+.

Authors:  D Mandal; T Mukherjee; S Sarkar; S Majumdar; A Bhaduri
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

Review 4.  Anti-leishmanial and anti-trypanosomal natural products from endophytes.

Authors:  Jean Baptiste Hzounda Fokou; Darline Dize; Gisele Marguerite Etame Loe; Moise Henri Julien Nko'o; Jean Pierre Ngene; Charles Christian Ngoule; Fabrice Fekam Boyom
Journal:  Parasitol Res       Date:  2021-01-06       Impact factor: 2.289

5.  Enhanced action of amphotericin B on Leishmania mexicana resulting from heat transformation.

Authors:  H Ramos; J Milhaud; B E Cohen; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

6.  Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro.

Authors:  Cécile Ménez; Marion Buyse; Madeleine Besnard; Robert Farinotti; Philippe M Loiseau; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2006-09-11       Impact factor: 5.191

7.  A chemically modified tetracycline (CMT-3) is a new antifungal agent.

Authors:  Yu Liu; Maria E Ryan; Hsi-Ming Lee; Sanford Simon; George Tortora; Carol Lauzon; Michael K Leung; Lorne M Golub
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

8.  Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis.

Authors:  Cristiana T Trinconi; Juliana Q Reimão; Jenicer K U Yokoyama-Yasunaka; Danilo C Miguel; Silvia R B Uliana
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

9.  Identification of new leishmanicidal peptide lead structures by automated real-time monitoring of changes in intracellular ATP.

Authors:  J Román Luque-Ortega; José M Saugar; Cristina Chiva; David Andreu; Luis Rivas
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

10.  Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.

Authors:  M A Collier; K J Peine; S Gautam; S Oghumu; S Varikuti; H Borteh; T L Papenfuss; A R Sataoskar; E M Bachelder; K M Ainslie
Journal:  Int J Pharm       Date:  2016-01-05       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.